Comparison · updated November 3, 2026

Embody vs MEDVi: Embody for a simple cash-pay injection plan, MEDVi to explore more treatment formats

Embody is our starting recommendation for a cash-paying reader who wants a compounded injection and a clearly priced one-month option.

These two prices are different kinds of bill, so read the line under each price before you compare them.

Both providers pay us a commission through our links. Our recommendation reflects the needs described here; commissions do not set scores. How we make money

This content was researched and written with AI assistance. MEDVi referral links are affiliate links: we may earn a commission if you sign up. This is independent information, not medical advice or a clinical review.

Who each one suits

Embody is our starting recommendation for a cash-paying reader who wants a compounded injection and a clearly priced one-month option. Its public semaglutide catalogue plan is $79 with medication included. MEDVi is worth exploring when treatment format matters more: it lists oral and injectable routes. Our choice comes down to the prescribed product, the ongoing bill and the care you want. The detailed sections below explain MEDVi's dated price and regulatory records so you can make that choice with context.

Sources: Embody catalogue and payment terms · Medvi program

By Iacob Pastina, Independent Researcher & Publisher
Updated · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

Embody vs MEDVi side by side

Embody and MEDVi compared fact by fact
EmbodyMEDVi
Pricefrom $49/mo$99(affiliate link)First month, then $199 per refill; confirm the refill interval
MedicineCompounded onlyBrand-name and compounded
Needle-free optionNot listedYes, a pill or other oral form
InsuranceBothNo insurance listed
ConsultationBothIncluded
ShippingBothFree
Where it ships49 states plus DC, all except LouisianaNot published
Trustpilot3.8 / 5 across 10,100 reviews4.3 / 5 across 15,014 reviews
BBB ratingD+ (not accredited)F (not accredited)
Our score7.6/10 Good7.2/10 Good
Assessment limitsBothChecked Oct 16, 2026; a rating claim didn't match Trustpilot.

What Embody and MEDVi plans cost

Embody

Four published plan lengths for each injection. A sale advertised October 27 through December 1, 2026 cut the twelve-month prepaid amounts to $588 for semaglutide and $1,188 for tirzepatide; one-month plans stayed at $79 and $129.

All 8 Embody plans

Payments are normally non-refundable; a limited medical-disqualification exception applies.

How Embody bills

The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.

We checked Embody's prices on October 27, 2026.Every Embody price and plan

Embody’s GLP-1 website is joinem.co. GLP-1 Picks is an independent comparison site.

Want Embody on its own? Read our Embody GLP-1 review to see what you pay for semaglutide or tirzepatide and what customer reviews say, or check is Embody legit for its BBB, Trustpilot and FDA records.

MEDVi(affiliate link)

Compounded semaglutide tablets and injections, a separate compounded tirzepatide injection, and brand-name Wegovy and Zepbound paths with a $99 membership plus medication.

All 5 MEDVi plans
How MEDVi bills

First month: $99 for compounded semaglutide injection with no contract, then $199 per refill. The landing page does not state the refill interval; MEDVi's April to August 2026 replies to BBB complaints described 28-day renewals. Confirm the interval and next charge. No verified annual payment count.

We checked MEDVi's prices on November 3, 2026.

Where Embody wins on price

Embody's public catalogue lists compounded semaglutide at $79 for one month and tirzepatide at $129, with lower monthly equivalents on longer prepaid terms. Its yearly-plan sale, advertised October 27 through December 1, 2026, was $588 prepaid for semaglutide or $1,188 for tirzepatide, equivalent to $49 or $99 per month. Confirm current and renewal terms. MEDVi's landing page, checked November 3, 2026, lists compounded semaglutide at $99 for the first month with no contract and $199 per refill, without stating the refill interval. For the first month of semaglutide injections, Embody lists $79 on its one-month plan and MEDVi lists $99. The $49 annual-plan sale equivalent, advertised through December 1, 2026, required $588 upfront; MEDVi's $199 refill price has no stated interval, so it does not establish a comparable recurring monthly cost.

The trade-off is choice. Embody's September 3 catalogue lists compounded semaglutide and tirzepatide injections; its former oral tirzepatide gum is absent. MEDVi lists compounded semaglutide injections and dissolvable tablets, plus a separate compounded tirzepatide injection on its dedicated page checked October 8, 2026. That compounded offer's full commitment and renewal terms remain unconfirmed; the $99/$199 semaglutide schedule is not its price. Branded Zepbound is another distinct path: its listed $99 membership excludes medication and is not a complete treatment price.

Sources:Embody published product catalogue· Current MEDVi offer (affiliate link)(affiliate link)· MEDVi injection costs and pharmacy details· MEDVi compounded tirzepatide source

Where MEDVi wins on formats and customer ratings

MEDVi offers more ways to take treatment. It lists oral tablets and injections for compounded GLP-1 care, while Embody's September 3 catalogue lists injections only; its former tirzepatide gum is absent. Both now name pharmacy partners: MEDVi lists RedRock Pharmacy, Beaker Pharmacy & Compounding and Triad Rx; Embody lists Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx.

The dated Trustpilot readings differ: MEDVi showed 4.3/5 across 15,014 reviews on October 15, 2026, while Embody showed 3.8/5 across 10,100 on October 17. Embody's profile includes merged reviews. Do not treat either rating as clinical-quality evidence. MEDVi had an unaccredited F rating at the BBB with 763 complaints in three years on October 15. Embody's shared operator showed D+, not accredited, with 245 company-wide complaints on October 17; the profile also lists SnagRx and RodeoMeds as alternate names. That total is neither Embody-only nor a count of unresolved cases.

Sources:MEDVi on Trustpilot· MEDVi pharmacy terms· MEDVi at the BBB· Embody on Trustpilot· Embody's shared operator at the BBB

What the FDA record changes

The FDA issued warning letter #721455 to MEDVi on February 20, 2026. The agency says MEDVi-branded labels implied MEDVi compounded the products when it did not, and that website comparisons implied compounded semaglutide and tirzepatide were equivalent to or FDA-evaluated like approved brands. This is a misbranding and marketing action, not an allegation that the medication was unsafe.

Our published rubric shows the FDA warning letter as a dated alert alongside the score word. FDA's database still showed no response or close-out letter for MEDVi on October 16, 2026. MEDVi's current score is 7.2 out of 10, including certification verified directly with LegitScript on October 21; the broader criterion assessment remains dated October 16. Certification does not resolve the FDA warning letter. MEDVi gets no scoring exception because it is an affiliate partner.

Sources:FDA warning letter #721455· LegitScript certification for medvi.org· Our scoring methodology

What to watch for with Embody and MEDVi

Embody

  • Payments are normally non-refundable. If Embody's provider determines medical disqualification, its refund policy allows a refund for unused services after deducting services already provided. Cancellation otherwise stops future renewal. During the sale advertised through December 1, 2026, the twelve-month semaglutide plan committed $588 up front; cancellation requests must reach support at least 72 hours before the next billing date.
  • The $49/$99 sale rates, advertised through December 1, 2026, required twelve-month prepayment of $588/$1,188 rather than monthly payments. Confirm any current price, the renewal amount and its date for your selected plan before paying.
Embody's strengths, cautions and terms

Strengths

  • The October 27, 2026 catalogue published four price tiers for each molecule: semaglutide $79/$76/$73/$49 and tirzepatide $129/$126/$123/$99 across one, three, six and twelve months. The twelve-month prices were a sale advertised through December 1, 2026, paid up front.
  • One-month injection prices of $79 for semaglutide and $129 for GLP-1 + GIP were visible in Embody's catalogue on September 20, 2026. The FAQ says the selected rate holds within the chosen plan.
  • Four plan lengths are disclosed (4, 12, 24 and 52 weeks), giving shoppers a shorter-term option as well as longer-plan pricing.
  • Publishes its cancellation and refund terms in full, dated August 25, 2026, so the 72-hour cancellation cutoff and limited medical-disqualification refund exception are readable before you pay.
  • Publishes responses to customer reviews on Trustpilot, giving readers the company's reply alongside individual complaints.

More to watch for

  • Trustpilot showed 3.8 / 5 across 10,100 reviews on October 17, 2026, while the landing page advertised 4.8 on our prior check. The Trustpilot profile includes merged reviews from another profile, and individual reports cover different pricing periods. It is not a measure of clinical quality.
  • Embody names four partner pharmacies: Red Rock Compounding Pharmacy in Utah, Health Warehouse in Kentucky, Precision Medicine in New York and Triad Rx in Alabama, and says all four are 503A compounding pharmacies. It does not say which one will fill your prescription. Triad Rx received a 2019 FDA warning letter for sterile-production violations, and the FDA close-out in May 2023 records that the firm no longer produces sterile drug products.
  • Embody's public catalogue lists only compounded injections; it doesn't list branded Wegovy, Zepbound, Mounjaro or Ozempic.
  • Modern Metabolic Medicine, Inc. also runs SnagRx (snagrx.com) and RodeoMeds (rodeomeds.com). Each footer names the shared parent, but none of the three names the others. Embody's October 27 catalogue listed a yearly-plan sale, advertised through December 1, 2026, with $49 semaglutide and $99 tirzepatide monthly equivalents; SnagRx has its own prices and payment terms. Read our SnagRx review, then compare Embody and SnagRx side by side.
Medicines listed
  • Compounded semaglutide (injectable)
  • Compounded tirzepatide (injectable)
Insurance
No insurance support listed
Consultation
Included
Shipping
Free
Prescribers
OpenLoop Health clinical network (individual credentials MD/NP/PA not publicly listed before signup)
Lab work
Not disclosed
States
49 states plus DC, all except Louisiana. In Nebraska, service is limited to patients 19 and older (verified 2026-09-03)
Cancellation
Choose a monthly, 3-, 6- or 12-month plan at signup. Cancellation requests must reach support at least 72 hours before the next billing date, and the policy dated August 25, 2026 says all payments are final and non-refundable, with a refund for unused services on provider-determined medical disqualification, after deductions for services already provided. Multi-month plans are non-refundable in whole and in part.

MEDVi

  • FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
  • Its third-party records conflict: Trustpilot shows 4.3 out of 5 across 15,014 reviews, and MEDVi invited 157 of the 200 newest reviewers, while the BBB grades MEDVi F, lists it as not accredited and counts 763 complaints in three years (we checked on October 15, 2026)
MEDVi's strengths, cautions and terms

Strengths

  • Compounded semaglutide tablets and injections, plus a separately advertised compounded tirzepatide injection
  • The landing page says the program is HSA and FSA eligible and includes dietician visits and care coaching, with a footnote making that subject to insurance and copay eligibility
  • $99 covers the first month of compounded semaglutide on MEDVi's landing page with no contract, and MEDVi says its $199 refills include the same program benefits

More to watch for

  • You pay $99 only for the first semaglutide month; each refill costs you $199, and the landing page does not say how often refills bill. MEDVi's replies to BBB complaints between April and August 2026 described 28-day renewals, so confirm the interval before you pay
  • Brand-name Wegovy and Zepbound paths add a $99 membership plus a medication cost the page does not publish, and the same page's hero says "No membership or hidden fees!" directly above those cards; availability is subject to change
  • No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Medicines listed
  • Semaglutide (compounded injectable)
  • Semaglutide (compounded oral tablets)
  • Tirzepatide (compounded injectable; full billing terms unconfirmed)
  • Wegovy (brand-name pill or injection; availability subject to change)
  • Zepbound (brand-name injection; availability subject to change)
  • Ozempic (brand-name path referenced in MEDVi disclosures)
Insurance
No insurance support listed
Consultation
Included
Shipping
Free
Prescribers
OpenLoop Health and CareGLP Affiliated P.C.s; individual clinician credentials are not disclosed before checkout
States
Not published. MEDVi's terms say "The Services are currently available to individuals located in certain states" and give the list only by emailing customer service. No state count or state list is shown on the site's contact, about, terms or FAQ pages (rendered check 2026-09-03)
Cancellation
Cancel by email or patient-portal chat at least 72 hours before the next billing date. The policy describes initial-no-service and unshipped-prepaid-month refund exceptions, but also says refunds are limited to medical disqualification. Get the applicable plan-specific refund terms in writing; cancelling future billing is not an unconditional refund.

Compounded medicines are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold. Read the FDA's explanation of the risks.

Embody vs MEDVi: common questions

Is Embody or MEDVi cheaper?

Embody publishes the lower starting rates: compounded semaglutide from $79 for one month (its $49/mo yearly-plan sale was advertised through December 1, 2026) and GLP-1 + GIP injections from $129/mo, compared with MEDVi's $99 semaglutide first month and $199 refills, whose interval MEDVi's landing page does not state.

Embody ties its advertised rates to a selected plan length, so compare the exact medication and commitment at checkout rather than treating either floor as a universal annual total.

Does Embody or MEDVi have better reviews?

MEDVi rates higher on Trustpilot (4.3 against Embody's 3.8 out of 5), but neither company is accredited at the BBB: MEDVi has an F, and Embody's parent company, which also runs SnagRx and RodeoMeds, a D+.

The dated review and complaint counts are in the section on formats and customer ratings above. None of these ratings measures the quality of your care.

Is Embody or MEDVi safer?

We cannot prove one provider's medication is safer from public records alone.

We can compare the regulatory and disclosure record: MEDVi received FDA warning letter #721455 for misleading labeling and marketing, while no FDA warning letter is recorded for Embody in our current safety database. The MEDVi letter does not allege unsafe medication. MEDVi names three pharmacy partners and Embody names four; neither disclosure proves medication quality by itself.

Should I choose Embody or MEDVi?

Consider Embody first if the lower advertised plan rate fits your medication and commitment.

Consider MEDVi if you specifically need its oral tablet formats or brand-name paths and have confirmed the separate product's full price. Its $99 first month and $199 refill apply to semaglutide injections, whose refill interval is unstated. Also weigh MEDVi's BBB F and FDA warning record. Both pay us a commission, so affiliate status does not break the tie.

Where these facts come from

Embody:prices checked October 27, 2026, score evidence assessed October 16, 2026.Read our Embody review

MEDVi:prices checked November 3, 2026, score evidence assessed October 16, 2026.Read our MEDVi review

We score on a published methodology, and partnership never changes a score or a fact here.

What should you compare next?